drugset / Trial / NCT05133297
The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to methotrexate.
Timeline
- Start
- 2022-02-16
- Primary completion
- 2022-12-19
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TLL018 | Unknown | 1 unknown | Oral |
| Subject | TLL018 | Unknown | 2 unknown | Oral |
| Subject | TLL018 | Unknown | 3 unknown | Oral |
| Comparator | Tofacitinib | Small molecule | 5 mg | Oral |